What is the Share Price of Symbiotec Pharmalab Limited?

Symbiotec Pharmalab Limited share price is ₹1,098.70 As on 08 September, 2026|07:39

Home
>
Stocks
>
Symbiotec Pharmalab Limited

Symbiotec Pharmalab Limited Share Price

Q: What is the Market Cap of Symbiotec Pharmalab Limited?

The Market Cap of Symbiotec Pharmalab Limited is ₹0 As on 08 September, 2026|07:39

Q: What is PE Ratio of Symbiotec Pharmalab Limited?

The P/E ratio of Symbiotec Pharmalab Limited is As on 08 September, 2026|07:39

Q: What is PB Ratio of Symbiotec Pharmalab Limited?

The PB ratio of Symbiotec Pharmalab Limited is inf As on 08 September, 2026|07:39

₹ 1,098.70 +20.45 (1.90%)
Updated on 07-09-2026 4:39 PM

Stock Rating

Pros 2

Cons 5

Symbiotec Pharmalab Limited Price Performance

Day's Low
₹1,068

Day's High
₹1,141

₹ 1,098.70

52-w low
₹934.2

52-w high
₹1,180

1,098.70

Day's open
₹1,068
Previous close
₹1,078.25
VWAP
₹1,116.55
Lower price band
₹879
Upper price band
₹1,318.40

Today's Market Action

The last traded share price of Symbiotec Pharmalab Limited was 1,098.70 up by 1.90% on the NSE. Its last traded stock price on BSE was 1,099.85 up by 1.94%. The total volume of shares on NSE and BSE combined was 3,392,213 shares. Its total combined turnover was Rs 378.78 crores.

Symbiotec Pharmalab Limited Medium and Long Term Market Action

Symbiotec Pharmalab Limited hit a 52-week high of 1,180 on 01-09-2026 and a 52-week low of 934.2 on 01-09-2026. The stock price of Symbiotec Pharmalab Limited is down by 0% over the last one month. Don't forget to check the full stock price history in the table below.

Symbiotec Pharmalab Limited Fundamentals

Market Cap (Cr): 0
Book Value (₹):
Stock P/E:
Revenue (Cr):
Total Debt (Cr):

Face Value (₹):
Roce (%):
ROE (%):
Earnings (Cr):
Promoter’s Holdings (%):

EPS (₹):
Debt to Equity:
Dividend Yield (%):
Cash (Cr):

Symbiotec Pharmalab Limited Mutual fund holdings and trends

FUND NAME	Quantity	Monthly Change (Qty)

Symbiotec Pharmalab Limited Shareholding Pattern

Similar Stocks

Company	Price	Market Cap (Cr)	P/E

About Symbiotec Pharmalab Limited

Data not available.

Symbiotec Pharmalab Limited FAQ's

What is Share Price of Symbiotec Pharmalab Limited?

What is the Market Cap of Symbiotec Pharmalab Limited?

What is PE Ratio of Symbiotec Pharmalab Limited?

What is PB Ratio of Symbiotec Pharmalab Limited?

What is the CAGR of Symbiotec Pharmalab Limited?

How to Buy Symbiotec Pharmalab Limited Share?

Can I buy Symbiotec Pharmalab Limited from Samco?

How do I buy Symbiotec Pharmalab Limited from Samco?

Financials

(*All values are in Rs. Cr)

Consolidated Financial Performace In Graph(Net Profit)

Standalone Financial Performace In Graph(Net Profit)

(*All values are in Rs. Cr)

Consolidated Financial Performace In Graph(Net Profit)

Standalone Financial Performace In Graph(Net Profit)

(*All values are in Rs. Cr)

Consolidated Financial Performace In Graph(Cash Flow)

Standalone Financial Performace In Graph(Cash Flow)

News

Review

Pros

Zero Debt
The company has almost nil to negligible debt to equity ratio of 0.00. Considering the fact that the business is debt free, equity shareholders shall carry lower risk of holding the stock.
Strong Working Capital Cycle
The company has a great working capital cycle of 0 days which results in lower investments in working capital and higher asset turnover. This reduces capital requirement of the business and drives RoE and cash flow generation positively. This is extremely positive for long term shareholders of the business.

Cons

Low Sustainable RoE
The company's sustainable return on equity is lower than the expected cost of capital which implies that the underlying business will destruct value over a period of time due to it's inability to generate superior returns on capital.
Low Return on Capital Employed
The company is unable to generate sufficient return on capital employed which impairs it's ability to generate high return for shareholders after accounting for taxes, interest and other non-equity stakeholders.
Poor Cash Flow Conversion
The business has very poor cash conversion ratio of only 0.00% of operating earnings getting converted into operating cash flow. This implies that increase in profits has not translated into higher cash flows for the business and incrementally higher investments in working capital which works negatively for shareholders.
Negative operating earnings and interest coverage
The company has a negative operating earnings and a negative Interest coverage ratio of 0.00 times which implies that the company has no operating earnings to pay for interest which is currently being paid out of capital and/or other income. This is extremely negative for shareholders.
Capital Intensive Business
The company operates an extremely capital intensive business with a low Asset turnover ratio of 0.00. A low asset turnover ratio negatively impacts RoE and reduces shareholder returns. Also due to the capital intensive nature of business, growth of the business would need to be funded either via increasing borrowings or diluting shareholders, both of which shall negatively impact shareholder value and returns.

Valuation Analysis

Margin of safety
(08/09/2026)

100

Margin of Safety Index: High

0% People are bullish about Symbiotec Pharmalab Limited

0 % People are bearish about Symbiotec Pharmalab Limited

What is your opinion about this Stock?

Historical Data

Date	Open	High	Low	Close	Volume	Daily Change %